TAVR Low Risk denied as not FDA-approved for this use by Aetna?

Aetna's specific coverage criteria for tavr low risk are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna May Deny TAVR for Low Surgical Risk as Not FDA-Approved

A "not FDA-approved" denial for TAVR in low-surgical-risk patients is one of the most clearly incorrect and thus most successfully appealed denial types. TAVR received FDA approval for use in patients with severe aortic stenosis across multiple surgical risk categories, including low surgical risk. If Aetna has issued this denial, it typically means one of three things: (1) the authorization request used an ambiguous or outdated procedure code that did not clearly reference the FDA-approved indication; (2) Aetna's internal system flagged the submission based on an outdated policy version; or (3) the clinical documentation did not explicitly tie the requested procedure to its FDA-cleared indication.

Because the FDA-approval status is a matter of regulatory record — not clinical opinion — this type of denial can usually be reversed quickly with a well-organized appeal that explicitly references the regulatory approval.

## Federal Appeal Rights

Under ACA §2719 and ERISA §503, you have the right to a full internal appeal and, if denied, an independent external review. External reviewers apply current regulatory and evidence standards, not insurer-internal policy. The external review window is generally within four months of final internal denial — confirm the deadline from your denial letter. Expedited review is available for urgent clinical situations.

## Appeal Process and Timeline

1. Obtain the denial letter and the applicable Aetna clinical policy. Confirm exactly what Aetna claims is "not FDA-approved" — the procedure, the device, or the specific indication. 2. File a Level 1 internal appeal with documentation of FDA-cleared status. 3. If upheld, request external review — independent reviewers will not accept a factually incorrect FDA-status denial. 4. File a state insurance department complaint in parallel if the denial is clearly inconsistent with publicly available FDA approval information.

## Documentation to Gather

• FDA clearance documentation: Your cardiologist or the device manufacturer can provide a reference to the FDA's public approval of TAVR for low-surgical-risk patients — including the specific indication approved.
• Correct procedure and diagnosis codes: Work with your facility's billing team to confirm the authorization request used the appropriate current procedural codes that correspond to the FDA-approved indication.
• Structural heart team letter: A letter explicitly stating that the requested procedure is being performed within the scope of the FDA-approved indication, for the documented diagnosis of severe aortic stenosis.
• Medical-necessity documentation: Even in a regulatory-error appeal, include the full medical-necessity package so that if any secondary question arises, it is simultaneously addressed.

## Criteria-Mapping Structure

For this denial type, the mapping is straightforward: identify each specific "not approved" claim Aetna made, then provide the regulatory rebuttal with a cited source for each. Document the FDA approval status, the specific indication approved, and confirmation that the request falls within that approved indication. Keep the rebuttal concise and factual — the strength of this appeal is regulatory clarity, not clinical argument.